Uncategorized
RadianceTx Raises $1 Million First Tranche to Develop Novel Glaucoma Therapy
TUCSON, Ariz. & LONDON--(BUSINESS WIRE)--RadianceTx™, a leader in ophthalmic therapeutic innovation, today announced a $1 million first tranche closing of a targeted $7 million round of financing. The investment will be used to fund development of the Company’s Beta Ophthalmic System for delivery of beta irradiation therapy to improve glaucoma surgery outcomes. Validated in three clinical studies conducted by preeminent ophthalmic research teams, beta therapy has been shown to improve glaucoma